PAREXEL APPOINTS GLENN C. VAN DEUSEN AS CORPORATE VICE PRESIDENT AND GENERAL MANAGER OF MEDICAL MARKETING SERVICES
BOSTON, MA, November 10, 2005 — PAREXEL International Corporation (Nasdaq: PRXL), a leading global bio/pharmaceutical services organization, today announced that Glenn C. Van Deusen has been appointed to the role of Corporate Vice President and General Manager of Medical Marketing Services. Mr. Van Deusen assumes global leadership for all medical marketing business units, including medical education and communications, exhibitions, meetings and events, reimbursement and patient assistance programs, health policy and scientific publications.
“Glenn brings to PAREXEL extensive expertise in commercializing bio/pharmaceutical products and medical devices, and we look forward to his contributions in growing our Medical Marketing Service businesses,” said Kurt Brykman, President of PAREXEL Consulting and Marketing Services. “Glenn is focused on expanding our abilities to translate science to action through the creation of high-level strategies, programs and communications that will help our clients successfully develop, launch and optimize their products.”
Mr. Van Deusen joins PAREXEL from Publicis Groupe, one of the world’s largest communications companies, where he held several executive-level positions. Most recently, he served as Executive Vice President and Managing Director of the Saatchi & Saatchi Healthcare Division. Mr. Van Deusen also brings to PAREXEL extensive client-side experience, having held senior business management positions at Advanced Polymer Systems and Bausch & Lomb, as well as brand management positions at Procter & Gamble and SmithKline Beecham.
Mr. Van Deusen is primarily based in Stamford, CT, and also manages global efforts from PAREXEL offices in Worthing, UK.
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS) and integration services. Headquartered near Boston, Massachusetts, PAREXEL operates in 52 locations throughout 38 countries around the world, and has approximately 5,230 employees.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", “estimates”, “projects”, “targets” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company’s Annual Report on Form 10-K for the Fiscal Year ended June 30, 2005 as filed with the SEC on September 8, 2005, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.